FDA Grants Permission to Enroll up to 8 Additional Secondary Progressive Multiple Sclerosis (SPMS) Patients in the Expanded Access Program with Intranasal Foralumab
05 avr. 2022 07h00 HE
|
Tiziana Life Sciences Ltd.
This Intermediate-Size Patient Population Expanded Access program will follow the same clinical dosing regimen as the two ongoing single-patient expanded access programs in SPMS patients.Tiziana...
Tiziana Announces Initiation of Phase 1b Clinical Trial in Crohn’s Disease Patients to Evaluate Oral Capsules of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody
25 mars 2022 07h00 HE
|
Tiziana Life Sciences Ltd.
This clinical trial, the first-ever oral immunotherapy for patients with mild-to-moderately active Crohn's Disease, is anticipated to be completed by Q4, 2022. NEW YORK, March 25, 2022 (GLOBE...
Tiziana Announces Availability of March 14 KOL Event Replay
15 mars 2022 14h15 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, March 15, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug...
Tiziana Life Sciences Hosting Key Opinion Leader Virtual Event to Discuss the Intranasal Delivery of Foralumab in Multiple Sclerosis
11 mars 2022 07h17 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, March 11, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of...
Tiziana Announces Positive Clinical Data from A Secondary Progressive Multiple Sclerosis Patient Treated for Six Months with Intranasally Administered Foralumab, A Fully Human Anti-CD3 Monoclonal Antibody
10 mars 2022 07h00 HE
|
Tiziana Life Sciences Ltd.
Intranasal foralumab was well-tolerated with no adverse reactions or laboratory abnormalities after 6 months of therapy and the patient chose to remain on therapyData show sustained inhibition of...
StemPrintER Demonstrates Prognostic Utility in TransATAC Cohort
01 mars 2022 09h05 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, March 01, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.’s (Nasdaq: TLSA) former subsidiary, AccuStem Sciences, Inc. (OTC PINK: ACMSY) (formerly AccuStem Sciences Ltd.), today...
Tiziana Life Sciences CEO to Present at Annual BIO CEO & Investor Conference
10 févr. 2022 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of...
Tiziana Announces Submission of Amendment to Investigational New Drug Application to Advance Oral Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, in Patients with Crohn’s Disease
04 févr. 2022 07h00 HE
|
Tiziana Life Sciences Ltd.
- Tiziana is Developing the First Oral Form of Foralumab in a Convenient Capsule to be Evaluated in Phase 1b Clinical Study NEW YORK, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd...
Tiziana Life Sciences to participate in a Fireside Chat At the B. Riley Securities 2022 Oncology Conference
26 janv. 2022 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (NASDAQ: TLSA) ("Tiziana" or the "Company"), a clinical-stage biopharmaceutical company developing breakthrough therapies for...
Tiziana Life Sciences Ltd. To Implement Stock Repurchase Program for up to $5 Million
24 janv. 2022 11h12 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) announced that its Board of Directors has today authorized the Company’s management to implement a stock...